Melanotan II
Melanotan II (Afamelanotide Precursor)
Also known as: MT-II, MT-2, Melanotan 2, Barbie drug
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
A melanocortin receptor agonist that produces skin tanning without UV exposure. Its sexual arousal side effect led to the development of PT-141. Carries significant safety concerns including potential effects on moles and melanoma risk.
Quick Facts
Not FDA-approved for human use. Research compound only. Afamelanotide (Scenesse), a related linear alpha-MSH analog, is approved for erythropoietic protoporphyria but is structurally distinct from Melanotan II.
Overview
Melanotan II is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) developed at the University of Arizona in the 1990s. It was originally designed as a sunless tanning agent — a compound that could darken skin pigmentation without ultraviolet radiation exposure, potentially reducing skin cancer risk.
Melanotan II acts as a non-selective agonist at melanocortin receptors (MC1R through MC5R). Its melanogenic effects are mediated primarily through MC1R on melanocytes, stimulating eumelanin production and transfer to keratinocytes. This produces a tan that develops over days to weeks and persists for extended periods.
During early clinical trials, researchers observed two significant side effects: increased sexual arousal and appetite suppression. The sexual arousal effect — particularly robust in both men and women — led to the development of PT-141 (bremelanotide), a modified version of Melanotan II optimized for sexual dysfunction rather than tanning.
Despite never receiving regulatory approval, Melanotan II has become one of the most widely used research peptides, particularly in tanning communities. This widespread unregulated use has raised significant safety concerns, particularly regarding its effects on melanocytic nevi (moles) and the theoretical risk of melanoma promotion.
Mechanism of Action
Melanotan II binds to all five melanocortin receptor subtypes with varying affinities. Its diverse biological effects reflect this non-selective receptor profile.
MC1R (melanogenesis): The primary target for tanning effects. MC1R activation on melanocytes triggers a cAMP-dependent signaling cascade that upregulates tyrosinase — the rate-limiting enzyme in melanin synthesis. This increases production of eumelanin (brown/black pigment) and its transfer to surrounding keratinocytes. The result is progressive skin darkening independent of UV exposure, though UV co-exposure accelerates the effect.
MC3R/MC4R (sexual function and appetite): MC4R activation in the hypothalamus modulates dopamine and oxytocin release, producing sexual arousal. MC3R/MC4R activation in appetite-regulating brain regions suppresses food intake. These are the same pathways targeted by PT-141 for sexual dysfunction.
MC4R/MC5R (other effects): MC4R activation contributes to the nausea commonly experienced with initial doses. MC5R activation influences exocrine gland function.
The cyclic structure of Melanotan II confers metabolic stability compared to linear alpha-MSH. The D-phenylalanine substitution enhances receptor binding potency and resistance to enzymatic degradation. However, the non-selective nature of its receptor binding is responsible for both its diverse effects and its side effect profile.
Research Summary
Melanotan II has been studied in Phase I and Phase II clinical trials, though development for tanning was not pursued to completion due to the non-selective receptor profile and safety concerns.
Phase I studies at the University of Arizona demonstrated dose-dependent skin darkening in fair-skinned volunteers, with melanin density increases measurable within 5 days of subcutaneous dosing. A 10-day course produced tanning comparable to weeks of moderate sun exposure. Nausea was the primary dose-limiting side effect.
Dermatological safety is the principal concern. Multiple case reports document changes in melanocytic nevi (moles) following Melanotan II use — including darkening, growth, and development of new nevi. Several case reports describe melanoma diagnosis temporally associated with Melanotan II use, though causality is difficult to establish. A 2017 systematic review identified 11 cases of melanoma diagnosed in Melanotan II users, noting that while correlation does not prove causation, the biological plausibility of melanocortin-driven melanoma promotion warrants concern.
The melanoma risk debate centers on whether stimulating melanocyte proliferation and melanogenesis could promote malignant transformation in predisposed cells. MC1R signaling has complex and sometimes contradictory roles in melanoma biology — it is protective against UV-induced DNA damage (via eumelanin production) but potentially proliferative when constitutively activated.
An Australian survey of Melanotan II users found that 43% reported changes in pre-existing moles. Cardiovascular effects (mild, transient blood pressure changes) and facial flushing are also commonly reported.
Afamelanotide (Scenesse), a linear alpha-MSH analog related to but structurally distinct from Melanotan II, was approved by the EMA in 2014 for erythropoietic protoporphyria — a condition where patients are extremely sensitive to sunlight. Its safety profile is better characterized than Melanotan II, but it targets a specific medical condition rather than cosmetic tanning.
Key References
Subcutaneous administration of a synthetic analog of alpha-melanocyte stimulating hormone in humans
Dorr RT, et al. · Journal of Investigative Dermatology (1996) · 10.1111/1523-1747.ep12348461
Phase I clinical trial demonstrating dose-dependent skin darkening in fair-skinned subjects with subcutaneous Melanotan II, establishing proof-of-concept for UV-independent tanning.
Melanoma and Melanotan: a concerning association
Hjuler KF, Lorentzen HF. · Clinical and Experimental Dermatology (2014) · 10.1111/ced.12380
Case report and literature review describing melanoma diagnoses temporally associated with Melanotan II use, discussing biological plausibility of melanocortin-mediated melanoma promotion.
The risks of using unlicensed tanning injections of melanotan: a systematic review
Nelson ME, et al. · Drug Safety (2017) · 10.1007/s40264-017-0571-6
Systematic review identifying 11 melanoma cases among Melanotan II users, along with documented nevi changes, cardiovascular effects, and other adverse events from unregulated use.
Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II
Wessells H, et al. · International Journal of Impotence Research (2000) · 10.1038/sj.ijir.3900539
Clinical study demonstrating Melanotan II produces penile erections and increased sexual desire in men, establishing the basis for PT-141 development.
Protocols
Loading phase (community protocol)
Community protocols typically start at 100–250 mcg to assess tolerance (nausea is common initially), then increase to 250–500 mcg daily during a 1–2 week loading phase. Some users combine with low-level UV exposure to accelerate results. Injections typically administered in the evening to minimize nausea impact.
Maintenance (community protocol)
After desired pigmentation is achieved, frequency is reduced to maintenance dosing. Individual maintenance requirements vary significantly based on skin type and desired color depth.
Intranasal (community protocol)
Less common than injection. Bioavailability via intranasal route is lower and less predictable. Requires reconstitution into a nasal spray formulation. Side effects may be milder due to slower absorption.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Nausea Very common with initial doses. Usually diminishes with continued use. Starting at lower doses and injecting in the evening reduces impact. Anti-nausea medication may help. |
| common | Facial flushing Warmth and redness of the face occurring within minutes of injection. Typically resolves within 1–2 hours. |
| common | Mole darkening and changes Existing moles may darken, enlarge, or change in appearance. New moles may appear. This is a significant safety concern — any mole changes should be evaluated by a dermatologist. |
| common | Appetite suppression MC3R/MC4R-mediated appetite reduction. Some users consider this a beneficial side effect. |
| common | Spontaneous erections (men) MC4R-mediated sexual arousal. Especially common during loading phase. This effect led to PT-141 development. |
| uncommon | Fatigue and drowsiness Some users report sleepiness after injection, which is why evening dosing is common. |
| uncommon | Injection site reactions Redness, pain, or small lumps at injection site. Rotating sites helps. |
| uncommon | Hyperpigmentation (localized) Uneven darkening, particularly in areas of prior sun damage, scars, or skin folds. |
Contraindications
- —History of melanoma or family history of melanoma
- —Dysplastic nevus syndrome or large number of atypical moles
- —Pregnancy or breastfeeding (insufficient safety data; melanocortin effects on fetal development unknown)
- —Active skin cancer of any type
- —Uncontrolled cardiovascular disease
- —Addison's disease or other conditions involving melanocortin pathway dysfunction
Interactions
- —Theoretical interaction with other melanocortin receptor agonists (PT-141, afamelanotide) — additive receptor activation
- —May interfere with dermatological monitoring — mole changes from Melanotan II complicate skin cancer screening
- —Potential interaction with blood pressure medications due to transient cardiovascular effects
- —May affect appetite-regulating medications through MC3R/MC4R overlap
Reconstitution & Storage
Related Peptides
Melanotan II is typically used as a standalone tanning agent. Its sexual arousal effects overlap with PT-141 (which was derived from it), so concurrent use would be redundant for that purpose. Some users combine it with low-dose UV exposure to accelerate melanogenesis, though this partially defeats the UV-avoidance rationale.